Flibanserin HSDD Clinical Trial Results May Not Be Generalizable, Panel Says
Executive Summary
Safety and efficacy results from the clinical trial program for Boehringer Ingelheim's Girosa (flibanserin) may not be generalizable to the broad population of premenopausal women with hypoactive sexual desire disorder, members of the FDA's Reproductive Health Drugs Advisory Committee said June 18